New potential target for treatment of diabetes

[PRESS RELEASE 2018-07-24] [This press release has been revised] Researchers at Karolinska Institutet have discovered that one of the building blocks in the calcium channels in the pancreatic beta cells play an important role in regulating our blood glucose values. Treatments aimed at this building block may be a new way to combat primarily type 2 diabetes the researchers suggest in an article in the scientific journal Cell Reports.

Beta cells in the pancreas produce the hormone insulin, which regulates the blood glucose level in our bodies. In diabetes, the beta cells have lost part or all of their function. Calcium ions (Ca2+) act as an important signal for the release of insulin. When blood glucose increases, this causes the levels of Ca2+ in the beta cells to increase, triggering the release of insulin. Under normal conditions the Ca2+ signal displays a specific regular pattern when the cells are stimulated by glucose. When, on the other hand, the beta cells are not able to release normal amounts of insulin, as in diabetes, this pattern changes.

The level of Ca2+ increases in the beta cell when a specific calcium channel, made up of several different building blocks, opens in the beta cell’s wall. Per-Olof Berggren’s research group at Karolinska Institutet has previously shown that one of the building blocks in the channel, the so-called β3 subunit, plays an important regulatory role.

“In our new study, we are able to show that beta cells from diabetic mice have an increased amount of the β3 subunit and that this causes an altered Ca2+ pattern, a reduced release of insulin, and thereby impaired blood glucose regulation,” says Per-Olof Berggren, Professor at the Rolf Luft Research Centre for Diabetes and Endocrinology at the Department of Molecular Medicine and Surgery at Karolinska Institutet, who led the study.

When the researchers reduced the amount of the β3 subunit in the beta cells in the diabetic mice, the Ca2+ signal normalised and thereby the release of insulin, resulting in better regulation of the blood glucose levels. They also saw that mice that totally lacked the β3 subunit demonstrated a better beta cell function and blood glucose regulation when they were given a diabetogenic diet. When the researchers tried transplanting beta cells without the β3 subunit into mice with diabetes, the blood glucose regulation of the mice improved.

Experiments with human beta cells showed that the release of insulin deteriorates with increased amounts of the β3 subunit.

“Our findings indicate that just this building block in the calcium channel can be a new target for treating type 2 diabetes. However, even in type 1 diabetes manipulation of the beta 3 subunit may be beneficial in order to establish better functioning insulin secreting beta cells for transplantation,” says Per-Olof Berggren.

The research was financed by the National Research Foundation of Korea (NRF), the Korea-Sweden Research Cooperation Programme, the Swedish Foundation for Strategic Research, the Swedish Diabetes Association, Karolinska Institutet’s Foundations and Funds, the Swedish Research Council, the Novo Nordisk Foundation, the Erling-Persson Family Foundation, the Strategic Research Programme in Diabetes at Karolinska Institutet, the European Research Council (ERC), the Knut and Alice Wallenberg Foundation, Skandia insurance company Ltd, the Diabetes and Wellness Foundation, the Berth von Kantzow Foundation, and the Stichting af Jochnick Foundation.

Per-Olof Berggren is managing director of the bioetech company Biocrine AB, and co-authors Martin Köhler and Shao-Nian Yang are consultants at the company. No other corporate interests have been reported.

Publication: “Blocking Ca2+-channel β3 subunit reverses diabetes”. Kayoung Lee, Jaeyoon Kim, Martin Köhler, Jia Yu, Yue Shi, Shao-Nian Yang, Sung Ho Ryu, and Per-Olof Berggren. Cell Reports, online 24 July 2018.

For more information, please contact:
Per-Olof Berggren, Professor
Department of Molecular Medicine and Surgery, Karolinska Institutet
Phone: +46 8-5177 57 31
Mobile: + 46 70-729 57 31
E-mail: per-olof.berggren@ki.se 

Karolinska Institutet is one of the world’s leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.

Tags: